Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Immunohistochemical expression of programmed cell death ligand-1 in non-small cell lung cancer (CROSBI ID 639967)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Pupić-Bakrač, Petra ; Hanžič, Nina ; Matušan- Ilijaš, Koviljka ; Štemberger, Christophe ; Bulat-Kardum, Ljiljana ; Ivančić, Aldo ; Lučin, Ksenija Immunohistochemical expression of programmed cell death ligand-1 in non-small cell lung cancer. 2016

Podaci o odgovornosti

Pupić-Bakrač, Petra ; Hanžič, Nina ; Matušan- Ilijaš, Koviljka ; Štemberger, Christophe ; Bulat-Kardum, Ljiljana ; Ivančić, Aldo ; Lučin, Ksenija

engleski

Immunohistochemical expression of programmed cell death ligand-1 in non-small cell lung cancer

Background: Programmed cell death ligand-1 (PD- L1) is a transmembrane protein expressed on different non-tumor as well as on tumor cells, serving them to evade detection and elimination by immune system. Lung cancer is the most common cancer in the world and non-small cell lung cancer (NSCLC) represents approximately 80% to 85% of all lung cancers. In the era of new molecular targeted therapies there is a constant need for the investigation of molecular substrate of cancer progression. Aim: To analyze the PDL-1 expression in NSCLC tumor cells (TC) and immune stromal cells (IC) and to compare it to usual clinicopathological parameters. Materials and Methods: Expression of PDL-1 was analyzed immunohistochemically in 110 surgically resected NSCLC tissue microarray samples, using Ventana ready-to-use PD-L1 (SP263) primary antibody. The histological score (H-score) was calculated by multiplying percentage and intensity of staining separately on TC and IC, and was compared to clinicopathological parameters. Results: The expression of PDL-1 was seen in TC as well as in different types of IC as membranous and cytoplasmic staining of different intensity. The median TC H-score was 8.12 (range 0-300), IC H-score was 14.04 (range 0-60) and they showed a significant correlation (p=0.002, rp=0.286). There was no significant difference in PDL-1 expression between different NSCLC histological types. Statistical analysis showed the association between higher level of TC and IC PDL-1 expression and higher histological grade (p=0.002 and p<0.001, respectively), higher pathological stage (p=0.011 and p=0.017, respectively), and advanced clinical stage (p=0.046 and p=0.027, respectively). Also, the level of TC PDL-1 expression correlated with the proliferative activity of tumor cells (p=0.022, rp=0.217), while higher level of IC PDL-1 expression showed the association with pleural infiltration (p=0.026). Conclusion: Our results indicate that PDL-1 may be involved in NSCLC progression, confirming its role as a target for PD-L1 inhibitors that showed benefits in clinical trials.

Immunohistochemistry ; Lung carcinoma ; non-small cell ; Programmed cell death ligand-1 ; Progression

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

2016.

nije evidentirano

Podaci o matičnoj publikaciji

Podaci o skupu

Global Students' Conference of Biomedical Sciences in Belgrade

predavanje

20.10.2016-23.10.2016

Beograd, Srbija

Povezanost rada

Kliničke medicinske znanosti